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In silico bioactivity descriptorsAbstract The aims of the present study were the synthesis, an original spectroscopic characteriza-
tion, an evaluation of antiproliferative activities and lipophilicity indices along with pharmacoki-
netic properties of a novel class of fused azaisocytosine-containing congeners. An optimized,
well-established and scalable general method for the synthesis of the target molecules (10–18) via
the [4+2] annulation strategy was worked out successfully, which enables reacting the
molar equivalents of 1-aryl-2-hydrazinylideneimidazolidine hydroiodides (1–9) and ethyl
4-nitrophenylglyoxylate upon gently heating in n-butanol containing triethylamine and further
refluxing in a solvent mixture n-butanol/DMF. The synthesis was hypothesized to proceed via keti-
mine intermediates that undergo intramolecular cyclization. All the synthesized compounds (10–18)
revealed antiproliferative effects in four tumour cell lines of the epithelial origin, exerting superior
cytotoxic activities in A549, HeLa and T47D cells to that of a reference drug – pemetrexed.
Especially the 12, 13, 14, 15 and 18 seem to be the most promising lead structures for designing
more selective cytotoxic agents as they have a lower toxicity for normal epithelial cells after 24-h
incubation period. In addition, a number of the innovative antimetabolite-type molecules have beenpharma-
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cokinetic properties of novel fused azaisocytpreselected that possess the optimum lipophilicity range significantly correlated with some in silico
bioactivity descriptors relevant to the satisfactory pharmacokinetic profile in vivo. Thus, these orig-
inal molecules might be useful as drug discovery leads to an early phase of drug design.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is still considered to be the second ‘‘killer” (after heart disease)
in the developed countries (Patrick, 2009). On the other hand, in clin-
ical treatment there is still a lack of cytotoxic agents that are selective
for neoplastic versus normal cells in spite of current progress in
chemotherapy of certain human tumours. An application of new cyto-
toxic (antiproliferative) agents in patients suffering from cancer is also
limited because of their harmful effects on the normal dividing cells as
well as by overlapping severe side effects of combined anticancer drugs
that are recently used in adjuvant chemotherapy (Denny, 2001). There-
fore, the rational design and development strategy allowing for the
prioritization of novel synthetic anticancer agents that show a selective
cytotoxicity for cancer over normal cells seems to be of great urgency
in the continuous search for novel more effective as well as more safer
cytotoxic agents.
A number of small molecular weight structures based upon the
privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one template
with the common phenyl moiety at the C-3 and the modified aryl sub-
stitution patterns at the N-8 have previously been shown to possess
remarkable antileukemic as well as antimetastatic activities (Fig. 1,
the structures I–VII) (Sztanke et al., 2009). The promising substituents
attached at the N-8 of this template such as: 4-MeOC6H4 in I,
monochloro-substituted phenyl moieties (mostly 2-ClC6H4 in II and
4-ClC6H4 in III) and dichloro-substituted phenyls (3,4-Cl2C6H3 in IV
and 2,5-Cl2C6H3 in V) have previously been identified as beneficial
for the antileukemic potency. In turn, some structures (e.g., those with
4-MeOC6H4 (I), 3-MeC6H4 (VI) and monochlorophenyl substitutions
such as 2-ClC6H4 (II), 3-ClC6H4 (VII) and 4-ClC6H4 (III)) have previ-
ously been described as capable of evoking significant antimetastatic
activities in human cervical epithelial cancer cells. Finally, the modifi-
cation at the N-8 portion of the privileged imidazotriazinone scaffold
in this class of compounds, followed by extensive in vitro testing, hasN
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osine-like congeners. Arabian Journal oled to the drug discovery lead (III), in which the 4-chlorophenyl moiety
was identified as the best substitution pattern for the enhanced selectiv-
ity. This compound is deprived of cytotoxic effects towards normal
cells, evokes enhanced dose-dependent viability decreases in human
myeloma cells and is of importance due to the anticipated antimeta-
static potential in human cervical epithelial cancer cells, as previously
described (Sztanke et al., 2009). The same lead structure (conforma-
tionally stable and currently being investigated as potential drug
candidate) has previously been proposed as useful for the subsequent
design of lower toxic anticancer agents from this class of isosteric
isomers of fused azacytosine-like congeners.
In view of the above findings and continuing our studies (Sztanke
et al., 2009, 2015; Janicka et al., 2013), we have designed
antimetabolite-type fused azaisocytosine-like congeners. Our interest
in these compounds results from their structural novelty, the possibility
of introducing various electron-donating and electron-withdrawing
substituents at the aromatic phenyl ring and the anticipated biological
activity as well as bioavailability. Therefore, the aim of the present
study was to develop an optimized and effective approach leading to
the synthesis of unknown angular nitrogen bicyclic molecules contain-
ing azaisocytosine-template (10–18) in order to perform, for the first
time, the investigations concerning their complete spectroscopic,
antiproliferative, lipophilic and pharmacokinetic properties.
Previous studies have found that antitumour active antimetabolite,
azacytidine, is readily deaminated in vivo to inactive 6-azauridine by
cytidine deaminase, whereas azaisocytosine is resistant to this enzyme
(Hwang et al., 1995; Pitha et al., 1966). Therefore, we have designed a
novel class of the compounds (e.g., fused azaisocytosine-containing
congeners) that as derivatives of the isosteric isomers of
6-azacytosine (that could probably be utilized as false building blocks
required for the DNA synthesis) may be of chemical as well as medical
relevance due to their anticipated resistance to cytidine deaminase.
Thus, the particular importance in these original molecules resultsN
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antimetabolites for combating cancer. All the designed molecules, fea-
turing modified substitution sites at the C-3 (e.g., para-nitrophenyl)
and the N-8 (e.g., phenyl and variously substituted phenyl moieties)
positions, are based on the drug-like 7,8-dihydroimidazo[2,1-c][1,2,4]
triazin-4(6H)-one template (Sztanke et al., 2009). This seems to be
an extremely good scaffold for the design of novel adenosine receptor
antagonists that may be of the anticipated benefit in the therapy of
diseases associated with angiogenesis, such as cancer and diabetic
retinopathy (Keisuke et al., 1993; Taliani et al., 2012) and in the treat-
ment and prevention of inflammatory diseases, mainly hepatic cirrho-
sis (Szuster-Ciesielska et al., 2012; Kandefer-Szerszen´ et al., 2014). The
selection of a substitution pattern on the phenyl ring at the N-8 of the
privileged scaffold in this novel class of compounds is stringently based
on prior scientific literature evidence (Sztanke et al., 2009, 2015) and
the synthetic approach is carried out to obtain innovative
antimetabolite-type molecules, revealing not only antiproliferative
effects against tumour cells but foremost a lower toxicity towards nor-
mal cells. The choice of the introduced para-nitrophenyl moiety at the
C-3 is based on previous research findings, which showed that this moi-
ety is capable of significantly enhancing antiproliferative activities of
successful antimetabolite-type analogues (Brulikova´ et al., 2011).
Moreover, it has been reported that some nitroaromatic-containing
molecules as tumour-activated prodrugs may be selectively activated
in cancerous tissue (Denny, 2001).
The aim of our cell-based anticancer investigations is to identify
novel antiproliferative active lead structures revealing more selectivity
for malignant (A549, HeLa, T47D and TOV112D) over normal (Vero)
cells of the same epithelial origin.
The novel aspect of our chromatographic measurements is to assess
the utility of three types of RPLC columns (IAM, cholesterol and
ISRP) with different stationary materials in systematic studies of the
lipophilicity of a novel class of molecules. The subsequent purpose
of these studies is to check the possibility of processing the determined
isocratic retention factors (logs k) in rational bioavailability predic-
tions (log BBpermeation, log BBdistribution, log KHSA, %F, fu, plasma,
Caco-2, Pe, jejunum) that were performed to identify novel lead struc-
tures with an optimum lipophilicity range that allows their satisfactory
pharmacokinetics. Moreover, principal component analysis is
employed with the goal of visualizing trends in data matrixes of chro-
matographic, partitioning and pharmacokinetic parameters character-
izing the title compounds (10–18).
2. Experimental protocols
2.1. Instrumentations and materials
Ethyl 4-nitrophenylglyoxylate of 98% purity was supplied
from Alfa-Aesar GmbH (Germany) and was sufficiently
pure to be used directly without further purification. Triethy-
lamine (Et3N) (Sigma–Aldrich, Germany) was dried over
anhydrous potassium hydroxide and distilled before use.
Anhydrous solvents for the synthesis (e.g., n-butanol,
N,N-dimethylformamide, methanol) were purchased from
Roth (Germany) and Merck (Germany) companies. Addition-
ally, the polar solvents, such as a distilled water and methanol,
were used to remove successfully a soluble by-product derived
from the synthetic approach, e.g., triethylammonium iodide
which was the explicitly better soluble in these solvents than
were the isolated solid final products (10–18). A Heidolph
rotary evaporator (Germany), working under reduced
pressure, was used to concentrate the volatile components of
the reaction mixture to a suitable volume after the completion
of the synthesis process. Melting point (m.p.) of each novel
congener was determined on a Boetius apparatus (Germany)Please cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
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pound was checked by thin-layer chromatography. For this
aim the routine preparative TLC analysis was carried out on
commercial Merck 0.2 mm SiO2 gel aluminium sheets (60
F-254) with a fluorescence indicator that allows to visualize
of each final product spot under UV light at an excitation
wavelength of 254 nm. The combustion microanalyses for each
element analyzed (C, H, Cl, N) were consistent within ±0.4%
of the theoretical values. 1H NMR spectra (that were observed
at 300 MHz for 1H nuclei) and 13C NMR spectra (that were
observed at 75 MHz for 13C nuclei) for all novel compounds
of this class (10–18) dissolved in deuterated dimethyl sulfoxide
(DMSO-d6) were carried out on a Bruker Avance 300 MHz
spectrometer. DEPT-135 experiments were done additionally
to fully assign carbon multiplicities for all the molecules that
were analyzed. All the chemical shifts are given as d values that
were downfield in relation to an internal standard, e.g., tetram-
ethylsilane (TMS) (d= 0.00 ppm). Chemical shifts are pro-
vided in parts per million (ppm), whereas the magnitudes of
coupling constants are reported in frequency units, e.g., hertz
(Hz). Signal multiplicities, used to describe signals, are
indicated as follows: s, singlet; d, doublet; t, triplet and m, mul-
tiplet. The reported retention times (tR) of solutes 10–18 were
determined on IAM column in 20 C (293 K), using as a
mobile phase 50% acetonitrile in the buffer adjusted to pH 7.4.
2.1.1. 1-Aryl-2-hydrazinylideneimidazolidine building blocks
(1–9)
The patented earlier biologically active and stable at room
temperature hydroiodide salts of 1-aryl-2-hydrazinylideneimi
dazolidines (1–9) (Sztanke, 2012) were employed as strongly
nucleophilic species. They were sufficiently pure to be used
directly in synthesis of the presented herein fused
azaisocytosine-like congeners.
2.1.2. A general procedure for the synthesis of a novel class of
3-(4-nitrophenyl)-8-aryl-7,8-dihydroimidazo[2,1-c]
[1,2,4]triazin-4(6H)-ones (10–18)
1-Aryl-2-hydrazinylideneimidazolidine hydroiodide (0.02 mol)
was suspended in 10 mL of n-butanol. Then, a slight molar
excess of dry triethylamine (2.9 mL) and the molar equivalent
of para-nitrophenylglyoxylate (0.02 mol) were added. The syn-
thetic process was conducted in the first instance by gently
heating of the starting reagents with stirring until the interme-
diate which appeared had fully crystallized. Then a relevant
amount of DMF was added until a complete intermediate solid
dissolution was accomplished during heating and stirring.
Thermal cyclocondensation proceeded on refluxing in the
resulting solvent mixture n-butanol-DMF with stirring, and
its progress was monitored by preparative TLC that showed
the process to be complete in 1–5 h. The boiling solution of
reaction mixture was filtered off to remove sparse insoluble
impurities and subsequently was concentrated to ca. half its
volume by evaporation of the volatiles under reduced pressure.
After cooling the concentrated mixture was subsequently kept
refrigerated, a complete precipitation of the final product
occurring after 3 h. Then a portion of the formed crude pro-
duct was filtered off, washed sequentially with three treatments
of water (5 mL) and with one or two treatments of cold metha-
nol (5 mL), and finally purified by recrystallization from the
solvent mixture DMF-methanol in the proportion as indicated, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
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again, and finally dried using a dry heat sterilizer (MOV-
212S-PE, Panasonic, Japan). The following novel compounds
(that are given underneath) were obtained in a pure solid state
by this general procedure.
2.1.2.1. 3-(4-Nitrophenyl)-8-phenyl-7,8-dihydroimidazo[2,1-c]
[1,2,4]triazin-4(6H)-one (10). Obtained in 69% yield, when
recrystallized from the solvent mixture DMF-MeOH (5:1)
had m.p. 291–293 C. Anal. Calcd for C17H13N5O3: C, 60.89;
H, 3.91; N, 20.89. Found: C, 61.10; H, 3.90; N, 20.81. 1H
NMR (300 MHz, DMSO-d6): d 4.26 (s, 4H, 2CH2), 7.18–
8.46 (m, 9H, aromatic protons: 5H, phenyl-H and 4H, 4-
nitrophenyl-H); 13C NMR (75 MHz, DMSO-d6): d 40.5 (C-6,
CH2), 45.5 (C-7, CH2), 119.1 (2CH), 123.3 (2CH), 124.0
(CH), 128.5 (2CH), 128.9 (2CH), 138.4 (C-100), 139.9 (C-10),
145.5 (C-40 0), 147.4 (C-3), 151.7 (C-8a), 152.1 (C-4); HPLC
IAM 293K (50% acetonitrile in buffer pH 7.4): tR = 1.54 min.
2.1.2.2. 3-(4-Nitrophenyl)-8-(2-methylphenyl)-7,8-dihydroimi-
dazo[2,1-c][1,2,4]triazin-4(6H)-one (11). Obtained in 53%
yield, when recrystallized from the solvent mixture DMF-
MeOH (3:1) had m.p. 210–211 C. Anal. Calcd for
C18H15N5O3: C, 61.89; H, 4.33; N, 20.05. Found: C, 61.67;
H, 4.34; N, 19.98. 1H NMR (300 MHz, DMSO-d6): d 2.31
(s, 3H, CH3), 4.07–4.36 (m, 4H, 2CH2), 7.31–8.39 (m, 8H, aro-
matic protons: 4H, 2-methylphenyl-H and 4H, 4-nitrophenyl-
H); 13C NMR (75 MHz, DMSO-d6): d 17.5 (CH3), 41.6 (C-6,
CH2), 48.0 (C-7, CH2), 123.3 (2CH), 126.9 (CH), 126.9
(CH), 127.1 (CH), 128.3 (2CH), 131.0 (CH), 136.0 (C-2’),
136.1 (C-10 0), 140.2 (C-10), 144.5 (C-40 0), 147.1 (C-3), 151.9
(C-8a), 153.2 (C-4); HPLC IAM 293K (50% acetonitrile in buffer
pH 7.4): tR = 1.84 min.
2.1.2.3. 3-(4-Nitrophenyl)-8-(4-methylphenyl)-7,8-dihydroimi-
dazo[2,1-c][1,2,4]triazin-4(6H)-one (12). Obtained in 72%
yield, when recrystallized from the solvent mixture DMF-
MeOH (9:1) had m.p. 278–280 C. Anal. Calcd for
C18H15N5O3: C, 61.89; H, 4.33; N, 20.05. Found: C, 62.11;
H, 4.32; N, 20.11. 1H NMR (300 MHz, DMSO-d6): d 2.33
(s, 3H, CH3), 4.24 (s, 4H, 2CH2), 7.28 (d, J= 8.4 Hz, 2H, aro-
matic protons: 4-methylphenyl-H-20 and H-60), 7.77 (d,
J= 8.5 Hz, 2H, aromatic protons: 4-methylphenyl-H-30 and
H-50), 8.30–8.45 (m, 4H, aromatic protons: 4-nitrophenyl-H);
13C NMR (75 MHz, DMSO-d6): d 20.4 (CH3), 40.5 (C-6,
CH2), 45.6 (C-7, CH2), 119.2. (2CH), 123.3 (2CH), 128.5
(2CH), 129.4 (2CH), 133.2 (C-40), 136.0 (C-10 0), 140.0 (C-10),
145.2 (C-40 0), 147.3 (C-3), 151.7 (C-8a), 152.1 (C-4); HPLC
IAM 293K (50% acetonitrile in buffer pH 7.4): tR = 1.34 min.
2.1.2.4. 3-(4-Nitrophenyl)-8-(2,3-dimethylphenyl)-7,8-dihy-
droimidazo[2,1-c][1,2,4]triazin-4(6H)-one (13). Obtained in
55% yield, when recrystallized from the solvent mixture
DMF-MeOH (2:1) had m.p. 274–276 C. Anal. Calcd for
C19H17N5O3: C, 62.80; H, 4.72; N, 19.27. Found: C, 62.58;
H, 4.73; N, 19.20. 1H NMR (300 MHz, DMSO-d6): d 2.19
(s, 3H, CH3), 2.32 (s, 3H, CH3), 4.06 (t, J= 8.9 Hz, 2H,
CH2), 4.31 (t, J= 8.9 Hz, 2H, CH2), 7.19–7.32 (m, 3H, aro-
matic protons: 2,3-dimethylphenyl-H), 8.29 (d, J= 9.1 Hz,
2H, aromatic protons: 4-nitrophenyl-H), 8.38 (d, J= 9.1 Hz,
2H, aromatic protons: 4-nitrophenyl-H); 13C NMRPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
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CH2), 48.3 (C-7, CH2), 123.3 (2CH), 124.7 (CH), 126.3
(CH), 128.3 (2CH), 129.6 (CH), 134.8 (C-20), 136.1 (C-10 0),
138.1 (C-30), 140.3 (C-10), 144.4 (C-400), 147.1 (C-3), 151.9
(C-8a), 153.4 (C-4); HPLC IAM 293K (50% acetonitrile in buffer
pH 7.4): tR = 1.33 min.
2.1.2.5. 3-(4-Nitrophenyl)-8-(2-methoxyphenyl)-7,8-dihy-
droimidazo[2,1-c][1,2,4]triazin-4(6H)-one (14). Obtained in
52% yield, when recrystallized from the solvent mixture
DMF-MeOH (7:1) had m.p. 286–287 C. Anal. Calcd for
C18H15N5O4: C, 59.18; H, 4.14; N, 19.17. Found: C, 58.98;
H, 4.15; N, 19.26. 1H NMR (300 MHz, DMSO-d6): d 3.85
(s, 3H, OCH3), 4.08 (t, J= 9.1 Hz, 2H, CH2), 4.31 (t,
J= 9.1 Hz, 2H, CH2), 7.04–7.54 (m, 4H, aromatic protons:
2-methoxyphenyl-H), 8.30 (d, J= 9.1 Hz, 2H, aromatic
protons: 4-nitrophenyl-H), 8.38 (d, J= 9.1 Hz, 2H, aromatic
protons: 4-nitrophenyl-H); 13C NMR (75 MHz, DMSO-d6):
d 41.5 (C-6, CH2), 47.3 (C-7, CH2), 55.8 (CH3O), 112.7
(CH), 120.6 (CH), 123.3 (2CH), 125.5 (C-10 0), 128.3 (2CH),
128.5 (CH), 129.4 (CH), 140.2 (C-10), 144.7 (C-400), 147.2
(C-3), 151.8 (C-8a), 153.6 (C-4), 154.8 (C-20); HPLC IAM
293K (50% acetonitrile in buffer pH 7.4): tR= 1.58 min.
2.1.2.6. 3-(4-Nitrophenyl)-8-(2-chlorophenyl)-7,8-dihydroimi-
dazo[2,1-c][1,2,4]triazin-4(6H)-one (15). Obtained in 61%
yield, when recrystallized from the solvent mixture DMF-
MeOH (6:1) had m.p. 272–274 C. Anal. Calcd for C17H12-
ClN5O3: C, 55.22; H, 3.27; Cl, 9.59; N, 18.94. Found: C,
55.01; H, 3.26; Cl, 9.56; N, 19.01. 1H NMR (300 MHz,
DMSO-d6): d 4.15 (t, J= 8.9 Hz, 2H, CH2), 4.36 (t, J=
8.9 Hz, 2H, CH2), 7.46–8.39 (m, 8H, aromatic protons: 4H,
2-chlorophenyl-H and 4H, 4-nitrophenyl-H); 13C NMR
(75 MHz, DMSO-d6): d 41.7 (C-6, CH2), 47.7 (C-7, CH2),
123.3 (2CH), 128.4 (2CH), 128.5 (CH), 129.9 (CH), 130.1
(CH), 130.3 (CH), 131.5 (C-20), 134.8 (C-10 0), 140.0 (C-10),
145.3 (C-40 0), 147.3 (C-3), 151.7 (C-8a), 153.5 (C-4); HPLC
IAM 293K (50% acetonitrile in buffer pH 7.4): tR = 1.39 min.
2.1.2.7. 3-(4-Nitrophenyl)-8-(3-chlorophenyl)-7,8-dihydroimi-
dazo[2,1-c][1,2,4]triazin-4(6H)-one (16). Obtained in 62%
yield, when recrystallized from the solvent mixture DMF-
MeOH (4:1) had m.p. 260–261 C. Anal. Calcd for
C17H12ClN5O3: C, 55.22; H, 3.27; Cl, 9.59; N, 18.94. Found:
C, 43.14; H, 3.26; Cl, 9.57; N, 18.87. 1H NMR (300 MHz,
DMSO-d6): d 4.26 (s, 4H, 2CH2), 7.24–8.46 (m, 8H, aromatic
protons: 4H, 3-chlorophenyl-H and 4H, 4-nitrophenyl-H); 13C
NMR (75 MHz, DMSO-d6): d 40.6 (C-6, CH2), 45.4 (C-7,
CH2), 117.1 (CH), 118.6 (CH), 123.3 (2CH), 123.5 (CH),
128.7 (2CH), 130.6 (CH), 133.4 (C-100), 139.6 (C-30), 139.8
(C-10), 146.0 (C-40 0), 147.5 (C-3), 151.6 (C-8a), 152.0 (C-4);
HPLC IAM 293K (50% acetonitrile in buffer pH 7.4):
tR = 1.40 min.
2.1.2.8. 3-(4-Nitrophenyl)-8-(4-chlorophenyl)-7,8-dihydroimi-
dazo[2,1-c][1,2,4]triazin-4(6H)-one (17). Obtained in 64%
yield, when recrystallized from the solvent mixture
DMF-MeOH (7:1) had m.p. 301–302 C. Anal. Calcd for
C17H12ClN5O3: C, 55.22; H, 3.27; Cl, 9.59; N, 18.94. Found:
C, 55.39; H, 3.28; Cl, 9.59; N, 18.89. 1H NMR (300 MHz,
DMSO-d6): d 4.25 (s, 4H, 2CH2), 7.52–8.45 (m, 8H, aromatic, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Synthesis, structure elucidation, and determination of antiproliferative activities 5protons: 4H, 4-chlorophenyl-H and 4H, 4-nitrophenyl-H); 13C
NMR (75 MHz, DMSO-d6): d 40.6 (C-6, CH2), 45.4 (C-7,
CH2), 120.6 (2CH), 123.3 (2CH), 127.7 (C-4
0), 128.6 (2CH),
128.8 (2CH), 137.4 (C-10 0), 139.7 (C-10), 145.8 (C-40 0), 147.5
(C-3), 151.6 (C-8a), 152.0 (C-4); HPLC IAM 293K (50% acetoni-
trile in buffer pH 7.4): tR = 1.83 min.
2.1.2.9. 3-(4-Nitrophenyl)-8-(3,4-dichlorophenyl)-7,8-dihy-
droimidazo[2,1-c][1,2,4]triazin-4(6H)-one (18). Obtained in
59% yield, when recrystallized from the solvent mixture
DMF-MeOH (8:1) had m.p. 340–342 C. Anal. Calcd for
C17H11Cl2N5O3: C, 50.51; H, 2.74; Cl, 17.54; N, 17.33. Found:
C, 50.32; H, 2.73; Cl, 17.48; N, 17.27. 1H NMR (300 MHz,
DMSO-d6): d 4.25 (s, 4H, 2CH2), 7.71–8.45 (m, 7H, aromatic
protons: 3H, 3,4-dichlorophenyl-H and 4H, 4-nitrophenyl-H);
13C NMR (75 MHz, DMSO-d6): d 40.6 (C-6, CH2), 45.4 (C-7,
CH2), 118.7 (CH), 120.2 (CH), 123.3 (2CH), 125.4 (C-4
0), 128.7
(2CH), 130.7 (CH), 131.3 (C-30), 138.5 (C-100), 139.5 (C-10),
146.2 (C-40 0), 147.5 (C-3), 151.5 (C-8a), 151.9 (C-4); HPLC
IAM 293K (50% acetonitrile in buffer pH 7.4): tR = 2.34 min.
2.1.3. An assessment of DNA synthesis and cytotoxicity
The carried out determination is based on the measurement of
the amount of the labelled synthetic nucleoside analogue, e.g.,
5-bromo-20-deoxyuridine (BrdUrd), incorporated into the cel-
lular DNA in place of thymidine during the nascent synthesis
phase in a panel of cells that were treated with the compounds
of interest. Cells treated only with the culture media served as
controls. A panel of four tumour cell lines (such as: A549
(ECACC 86012804) – human Caucasian lung carcinoma cells,
HeLa (ECACC 93021013) – human Negroid cervix epitheloid
carcinoma cells, T47D (ECACC 85102201) – human breast
carcinoma cells and TOV112D (ATCC CRL-11731) – human
ovarian malignant adenocarcinoma cells) and one normal cell
line (e.g., Vero (ECACC 88020401) – African Green Monkey
kidney cells) of the same epithelial origin were employed.
The used cell lines were sourced and cultured as described in
detail previously (Sztanke et al., 2015).
End-point determinations were performed on an enzyme-
linked immunosorbent assay (ELISA) reader (BIO-TEC
Instruments, USA) using a commercially available chemilumi-
nescent BrdUrd labelling and detection kit III (Roche Diag-
nostics, Indianapolis, USA) (Muir et al., 1990; Ellwart and
Dormer 1985; Magaud et al., 1988; Huong, 1991). Each freshly
prepared stock solution of the screened compound in dimethyl
sulfoxide (Sigma–Aldrich, Germany) of above 99.9% purity
and filtered through an aseptic 0.22 lm-pore-size syringe filter
(GE Water and Process Technologies, USA) was finally
diluted into the cell culture media to obtain its 50 lg mL1
concentration. The effect of each investigated solute at the
tested concentration on the BrdUrd incorporation was
assessed spectrophotometrically after 24-, 48- and 72-h periods
of incubation at standard conditions (37 C, 5% CO2, 90%
humidity) and compared to the untreated control cells. Table 1
specifies the percentage values of growth inhibition over a time
in malignant and normal cells for all novel compounds of
interest. These values were determined in the following
manner: at first mean absorbance levels of at least three
measurements taken from the repeated true independent
BrdUrd-based evaluations were derived; then these mean
values were converted into the per cent of growth inhibition.Please cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
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Slovakia) at a concentration of 0.23 mM (100 lg mL1) was
used as a positive control (Sztanke et al., 2015) for the DNA
synthesis and cytotoxicity measurements.
2.1.4. Chromatographic measurements
2.1.4.1. Reagents and materials. Acetonitrile (MeCN) of HPLC
grade was purchased from Merck (Darmstadt, Germany),
whereas both citric acid and Na2HPO4 were certified as being
of analytical purity and supplied from Avantor Performance
Materials (Lublin, Poland). For HPLC measurements a dou-
ble distilled water was used that was obtained using a
Direct-Q 3 UV apparatus (Millipore, Warsaw, Poland). The
buffer (used as a mobile phase component) was prepared from
0.01 mol L1 solutions of Na2HPO4 and citric acid that were
mixed together and finally filtered through a 0.45 lm-pore-
size syringe filter (GE Water and Process Technologies,
USA). It should be noted that the physiological pH value of
resulting buffer solution (7.4) was achieved purposefully (as
the corresponding to a normal blood pH range of humans,
e.g., 7.35–7.45) before mixing with acetonitrile as an organic
modifier.
2.1.4.2. HPLC experimental. HPLC measurements were per-
formed employing a Shimadzu Vp (Shimadzu, Izabelin,
Poland) liquid chromatographic system (which was equipped
with columns packed with different reversed-phase materials
as indicated below, a LC 10AT pump, a SPD 10A UV–VIS
detector, a SCL 10A system controller, and a Rheodyne injec-
tor valve fitted with a 20 lL loop). All measurements were per-
formed under the isocratic conditions at 20 C (293 K) as well
as 37 C (310 K). The measurement temperatures were con-
trolled by a CTO-10 AS chromatographic oven. In the investi-
gations values of the peak asymmetry factor for each solute
sample were in the acceptable range without none additional
peaks on the registered chromatograms. Single peaks of the
tested compounds were detected under middle ultraviolet
(MUV) light at 254 nm. The dead time values were measured
from the peaks of citric acid. The capacity factors were
calculated from average values, that were taken from at least
three independent experimental measurements. The following
equation was employed to calculate the retention factor, k:
k ¼ ðtR  t0Þ=t0
where tR is the retention time of the original compound that
was analyzed and t0 denotes the dead time which was estab-
lished by injection of a non-retained marker, e.g., citric acid.
For RPLC experiments three different stationary phases
that were employed were as follows: the IAM column IAM.
PC.DD2 100  4.6 mm i.d., 10 lm, manufacture number
43751 (Regis Chemicals Company, Morton Grove, Illinois,
USA), the cholesterol column Cosmosil Cholester,
75  2 mm i.d., 2.5 lm, manufacture number R75182 (Genore,
Warsaw, Poland) and the ISRP GFF II column, 150  4.6 mm
i.d., 5 lm, manufacture number 53310 (Regis Chemicals Com-
pany, Morton Grove, Illinois, USA).
Buffer-acetonitrile mixtures were employed as mobile
phases for RPLC measurements in which acetonitrile concen-
tration in the effluent (expressed as a volume fraction) was
equal to 0.4 u and 0.5 u, respectively. The prepared mobile
phases were filtered through a 0.45 lm-pore-size syringe filter, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Table 1 Growth inhibition ratios of normal and tumour cells by an effective concentration of novel small molecular weight fused
azaisocytosine-like congeners.
Compound R Incubation time Growth inhibition (%)a in cell lines
Vero A549 HeLa T47D TOV112D
10 H 24 h 40 ± 4.5 70 ± 7.2 80 ± 7.8 100 ± 12.2 80 ± 7.8
48 h 95 ± 10.6 90 ± 8.9 90 ± 10.1 100 ± 9.9 100 ± 12.0
72 h 100 ± 15.2 100 ± 12.4 100 ± 9.8 100 ± 10.6 100 ± 9.6
11 2-CH3 24 h 50 ± 6.5 75 ± 8.0 80 ± 8.2 60 ± 5.8 80 ± 6.6
48 h 75 ± 5.2 80 ± 7.9 90 ± 10.2 80 ± 7.9 90 ± 8.4
72 h 95 ± 9.8 100 ± 11.4 100 ± 12.4 90 ± 8.9 100 ± 9.5
12 4-CH3 24 h 10 ± 1.8 25 ± 2.4 85 ± 8.2 90 ± 10.2 80 ± 6.2
48 h 80 ± 7.5 50 ± 5.6 90 ± 8.6 100 ± 10.6 90 ± 5.2
72 h 100 ± 15.4 80 ± 7.9 100 ± 10.6 100 ± 12.1 95 ± 7.2
13 2,3-(CH3)2 24 h 15 ± 1.9 25 ± 3.0 75 ± 6.9 80 ± 7.8 50 ± 3.5
48 h 50 ± 3.8 75 ± 8.1 85 ± 8.1 95 ± 8.6 90 ± 6.7
72 h 90 ± 12.5 85 ± 8.0 90 ± 8.9 100 ± 10.8 100 ± 11.2
14 2-OCH3 24 h 10 ± 1.5 30 ± 2.7 85 ± 7.9 80 ± 6.8 80 ± 6.8
48 h 40 ± 5.6 75 ± 8.2 90 ± 10.5 90 ± 7.8 90 ± 8.8
72 h 75 ± 5.2 80 ± 8.8 100 ± 9.6 100 ± 9.5 100 ± 9.7
15 2-Cl 24 h 15 ± 1.2 50 ± 4.8 65 ± 5.9 90 ± 6.8 80 ± 5.9
48 h 50 ± 5.8 90 ± 8.9 80 ± 7.8 100 ± 9.2 100 ± 9.5
72 h 80 ± 8.2 100 ± 11.8 100 ± 12.1 100 ± 8.6 100 ± 10.8
16 3-Cl 24 h 75 ± 6.8 80 ± 7.9 85 ± 7.9 95 ± 5.8 80 ± 6.9
48 h 85 ± 7.9 100 ± 11.2 95 ± 9.5 100 ± 8.8 100 ± 8.8
72 h 100 ± 9.2 100 ± 9.8 100 ± 10.9 100 ± 9.8 100 ± 9.4
17 4-Cl 24 h 50 ± 4.8 75 ± 6.8 85 ± 8.2 95 ± 8.2 90 ± 6.5
48 h 100 ± 11.2 100 ± 9.8 90 ± 8.8 100 ± 11.7 100 ± 8.5
72 h 100 ± 10.6 100 ± 10.6 100 ± 10.5 100 ± 10.4 100 ± 9.2
18 3,4-Cl2 24 h 30 ± 3.2 80 ± 8.4 90 ± 7.8 95 ± 6.8 90 ± 7.5
48 h 70 ± 7.4 100 ± 12.2 100 ± 8.9 100 ± 8.8 100 ± 9.2
72 h 100 ± 12.5 100 ± 11.5 100 ± 10.5 100 ± 12.6 100 ± 7.5
A reference drug 24 h 5 ± 0.2 10 ± 0.9 5 ± 0.7 10 ± 0.8 nd
48 h 10 ± 1.1 30 ± 2.4 10 ± 0.9 20 ± 1.2 nd
72 h 20 ± 1.9 50 ± 2.8 20 ± 1.5 30 ± 2.2 nd
Normal epithelial cell line: Vero – (ECACC 88020401) – African Green Monkey kidney cells.
Cancer cell lines of the epithelial origin: A549 (ECACC 86012804) – human Caucasian lung carcinoma cells; HeLa (ECACC 93021013) – human
Negroid cervix epitheloid carcinoma cells; T47D (ECACC 85102201) – human breast carcinoma cells; TOV112D (ATCC CRL-11731) – human
ovarian primary malignant adenocarcinoma cells.
An effective concentration of 50 lg mL1 corresponds to the following millimolar concentration values: 0.149 mM (10), 0.143 mM (11, 12),
0.138 mM (13), 0.137 mM (14), 0.135 mM (15, 16, 17), 0.124 mM (18).
A reference drug – pemetrexed at a concentration of 100 lg mL1 (0.23 mM) (Sztanke et al., 2015).
nd – not determined.
a Each value is the mean of at least three independent experiment values ± standard deviation.
6 M. Sztanke et al.(GE Water and Process Technologies, USA) before using
them. Retention data were recorded at the flow rate of the fol-
lowing: 1.2 mL min1 with the IAM column, 0.4 mL min1
with the Cosmosil Cholester column and 0.6 mL min1 with
the ISRP column.Please cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal o2.1.4.3. In silico calculations. The partition lipophilicities,
expressed as log P values of the compounds of interest in the
n-octanol–water system, as well as the molecular descriptors
that are relevant to their pharmacokinetics (log BBpermeation,
log BBdistribution, log KHSA, %F, fu, plasma, Caco-2, Pe, jejunum), determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Synthesis, structure elucidation, and determination of antiproliferative activities 7were calculated using an ACD/Percepta software (Ło´dz´,
Poland). In silico calculations were carried out exploiting the
Abraham’s linear solvation energy relationships (Kaliszan,
2007; Vitha and Carr, 2006).
2.1.4.4. Statistical calculations. Multivariate data analyses,
e.g., principal component and cluster variables analyses, and
the regression analysis have been done using a chosen
Minitab 16 statistical software (Minitab Inc., State College,
Pennsylvania, USA).
3. Results and discussion
3.1. Synthesis and spectroscopic characterization of a novel class
of fused azaisocytosine-containing congeners (10–18)
The patented biologically active 1-aryl-2-hydrazinylideneimida
zolidines (1–9) (Sztanke, 2012) were exploited (as excellent
nucleophilic centred building blocks) in synthesis of novel
3-(4-nitrophenyl)-8-aryl-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-
4(6H)-ones (10–18).
The target fused azaisocytosine-like congeners (10–18),
comprising in their structures the incorporated
6-azaisocytosine template, were successfully prepared employ-
ing the general synthetic pathway, as shown in Scheme 1. An(i), (
NH
N
N
N
EtO
O
10-18
(1-9) HI
N
N
N
N
O
R
Et
R
+
R
NH
N
NH2
N
- EtO
1,10: R = H; 2,11: R = 2-CH3; 3,12: R = 4-CH
6,15: R = 2-Cl; 7,16: R = 3-Cl, 8,17: R = 4-Cl; 9,
Reagents and conditions: (i) n-BuOH, Et3N, reflu
Scheme 1 A scheme for the synthesis of 3-(4-nitrophenyl)-8-ary
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a patent pending synthetic approach of that novel class of
compounds (Sztanke and Sztanke, 2014a,b). It is clear that
in this case a new 1,2,4-triazinone template was annelated to
the existing four atoms’ fragment (NACANAN) of nucle-
ophilic centred hydrazinylideneimidazolidines employing ethyl
para-nitrophenylglyoxylate (as an excellent electrophilic donor
of the two carbon atoms’ fragment (CAC‚O)) according to
the [4+2] pattern (Rusinov et al., 2008). For this purpose,
the molar equivalents of the available hydroiodide salts of
hydrazinylideneimidazolidines bearing various substitution
patterns on the phenyl ring (1–9) were successfully treated with
ethyl para-nitrophenylglyoxylate in the suitable reaction media
under basic conditions. Initially, the condensation process was
conducted by gently heating the above starting materials in
n-butanol medium containing a small molar excess of triethy-
lamine leading to the formation of suitable ketimine intermedi-
ates (drawn in square bracket in Scheme 1). In this case the
nucleophilic attack of the most reactive exocyclic amino-type
nitrogen of hydrazono moiety to the reactive electrophilic car-
bonyl carbon at the position next to the ester group took place.
The step of condensation would be expected to proceed with a
concomitant removal of water molecule, and additionally led
to an evolution of the hydrogen iodide from the reaction mix-
ture which had reacted with Et3N to give triethylammoniumNO2
ii)
NO2
O
O
O
NO2
H
3; 4,13: R = 2,3-(CH3)2; 5,14: R = 2-CH3O; 
18: R = 3,4-Cl2
x, 2-10 min. (ii) n-BuOH/DMF, reflux, 1-5h
l-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones (10–18).
, determination of antiproliferative activities, lipophilicity indices and pharma-
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8 M. Sztanke et al.iodide (Et3NH
+I) as a by-product of alkylation. Subse-
quently, ketimine-type intermediates, containing the proto-
nated endocyclic N3 nitrogen, are cyclized on heating in an
inert refluxing n-butanol/DMF mixture to novel fused
azaisocytosine-like congeners (10–18) with a concomitant loss
of ethanol molecule. The results of combined 1H NMR/13C
NMR investigations have fully defined the structures of final
products that are based on the privileged 7,8-dihydroimidazo
[2,1-c][1,2,4]triazin-4(6H)-one template. Moreover, the oppo-
site mode of cyclization to 3-(4-nitrophenyl)-7-aryl-5H-6,7-
dihydroimidazo[2,1-c][1,2,4]triazole derivatives (that has also
been thoroughly investigated) proved to be impossible under
the established reaction conditions since no traces of such type
of compounds were detected in the clear spectroscopic data of
the final products. It is now believed that thermal cyclization
of intermediates to the desired products proceeds in the direc-
tion which yields the most stable cyclic products possessing the
least energy.
The complete spectroscopic characterization of novel fused
azaisocytosine-like congeners (10–18) is specified in Subsection
2.1.2. describing the experimental protocols. The title
compounds (10–18) exhibited 13C NMR chemical shifts of
the C7 atoms at d in the region 45.4–48.3 ppm, whereas the
corresponding lower shifts of the C6 atoms were found to be
at d in the region 40.5–41.7 ppm. These findings proved that
there are two endocyclic methylene groups (in the five-
membered imidazolidine ring) that reveal an unequal chemical
character. Obviously these secondary methylene carbon atoms
(C6 and C7) were unambiguously identified as the signals that
go down, when analysing the results of DEPT-135 experiment.
1H NMR chemical shifts of the aromatic proton signals
(derived from two rings attached to the bicyclic scaffold) were
found to be at d in the region 7.04–8.46 ppm, as indicated in
the case of all the compounds (10–18). However, the
compound 13 revealed the proton signals derived from the
para-nitrophenyl ring (as two doublets in the aromatic region
at d 8.29 ppm and d 8.38 ppm with coupling constants of
J= 9.1 Hz and 9.1 Hz, respectively, integrating with two pro-
tons each) that were shifted the most downfield from those
proton signals of the second 2,3-dimethylsubstituted phenyl
ring (7.19–7.32 ppm).
In the present study we have optimized the general syn-
thetic process by an adequate choice of reagents, solvents
and suitable conditions that were required to synthesize the
desired final products. It has been proved that the synthesis
of novel fused-azaisocytosine-containing congeners (10–18),
although conducted under mild conditions, proceeded with rel-
atively good overall yields. Higher yields were obtained when
the cyclization of the hypothetical intermediate ketimine-type
Schiff bases was carried out for the suitable reaction period
in refluxing n-butanol/DMF solvent mixture containing a
small molar excess of Et3N. The general synthetic procedure
was developed in the present study on a multi-gram scale that
could be applicable to a number of identifiable derivatives of
this novel class.
Preparative procedures of the title compounds as well as
reactions of 1-aryl-2-hydrazonoimidazolidine derivatives with
ethyl para-nitrophenylglyoxylate have not been reported in
the scientific literature yet, including Chemical Abstracts
Service (CAS). Thus, this not studied in the past approach for
the synthesis of an unknown class of fused azaisocytosine-
like congeners (with the common 4-nitrophenyl moiety at thePlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
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time presented. As the synthesized compounds contain a nitro
substitution on the aromatic phenyl ring they could be utilized
in further synthesis of arylamines as well as aryldiazonic salts
and their related derivatives.
The initial formation of the suitable ketimine-type Schiff
bases, e.g., ethyl (2Z)-(4-nitrophenyl)[(2E)-(1-arylimidazolidin-
2-ylidene)hydrazinylidene]acetates (II), as intermediates in the
synthesis of final products (10–18), probably proceeds through
an intermediate stage according to the mechanism that may
be represented by Scheme 2. A nucleophilic attack of an
amine-type nitrogen of the suitable hydrazinylideneimidazo-
lidine to an electrophilic a-carbonyl carbon of ethyl para-
nitrophenylglyoxylate results in the formation of hemiaminal
(I), e.g., ethyl hydroxy(4-nitrophenyl)[(2E)-2-(1-arylimidazolidin-
2-ylidene)hydrazinyl]acetate. Its further conversion into the
suitable ketimine (II) followed with concomitant dehydration is
accomplished by deprotonation of the nitrogen in hemiaminal
molecule and pushing the oxygen off of the carbon by the
electrons of the same nitrogen atom. The first reversible step
of this reaction is believed to be largely dependent on the rate
of dehydration of I.3.2. In vitro antiproliferative activities of novel
3-(4-nitrophenyl)-8-aryl-7,8-dihydroimidazo[2,1-c]
[1,2,4]triazin-4(6H)-ones (10–18)
The designed and synthesized fused azaisocytosine-like con-
geners (10–18) were screened thoroughly for their in vitro
antiproliferative effects (measured by BrdUrd incorporation)
against a panel of five reference cell lines (A549, HeLa,
T47D, TOV112D and Vero) of the same epithelial origin. An
efficient, reliable and reproducible BrdUrd-ELISA method is
a derivative of the traditional radioactive [3H]-thymidine
incorporation assay. The main advantage of this approach is
that it permits a quantitative estimate of the incorporation of
the labelled nucleoside analogue (as the fraudulent thymidine
precursor) without the possibility of working with radioactive
isotopes (Sztanke et al., 2015). The employed assay is com-
monly accepted in the preliminary phase of the discovery pro-
cess directed towards development of novel anticancer agents
(Vega-Avila and Pugsley, 2011). The BrdUrd-based method
proved to be as sensitive as [3H]-thymidine assay in previous
in vitro investigations (Muir et al., 1990; Hawker, 2003).
According to the manufacturer’s protocol the results obtained
with these two assays are strongly correlated together.
Table 1 specifies the percentage growth inhibition ratio of
both tumour and normal cells by the 50 lg mL1 concentra-
tion of all fused azaisocytosine-like congeners (10–18) after
24-, 48- and 72-h periods of incubation. Table 2 lists the
IC50 values (the half maximal inhibitory concentrations calcu-
lated from the concentration-dependent inhibition curves) for
the examined compounds.
All novel 3-(4-nitrophenyl)-8-aryl-7,8-dihydroimidazo[2,1-
c][1,2,4]triazin-4(6H)-ones (10–18) exerted a cytotoxic effect
in the majority of recruited tumour cells. It should be noted
that all molecules at an effective concentration (50 lg mL1)
revealed significantly higher antiproliferative effects in three
malignant cells (A549, HeLa and T47D) than those evoked
by the 100 lg mL1 concentration of commonly used folate
antimetabolite – pemetrexed (Sztanke et al., 2015). Pemetrexed, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Scheme 2 The proposed stepwise mechanism for the formation of ketimine-type Schiff bases (II).
Synthesis, structure elucidation, and determination of antiproliferative activities 9was employed in our studies as a standard drug, since this con-
gener of folic acid is clinically used in patients suffering from
non-small cell lung cancer. The inhibition of proliferation of
tumour cells by the investigated congeners having incorpo-
rated fused azaisocytosine template is thought to be due to
competition for nucleotides required for DNA biosynthesis
(Rusinov et al., 2008).
Analysing the antiproliferative activities of the target fused
azaisocytosine-containing congeners with the phenyl, alkyl-
phenyl, dialkylphenyl and alkoxyphenyl substitution pattern
at the N-8 (10–14) it has been noticed that the parent
compound (10), with an electron-rich phenyl ring, is more
cytotoxic for T47D, A549 and TOV112D cells than are either
its substituted derivatives. However, the most promising com-
pounds seemed to be 12 and 14 (bearing the electron-donating
para-CH3 and ortho-CH3O group, respectively, at the phenyl
ring) because they possess the highest cytotoxic activity against
HeLa cells, displaying only a slight toxicity on normal cells
after a 24-h incubation period.
Amongst the compounds bearing the mono- and dichloro-
phenyl substitution at the N-8 of the template (15–18), the
derivatives 16, 17 and 18 (that have electron-withdrawing
groups attached at meta-Cl, para-Cl and 3,4-Cl2 position,
respectively, of the phenyl ring) were chosen as capable of pro-
ducing the highest cytotoxic effects in T47D cells. The highest
antiproliferative activities in TOV112D cells were achieved by
introducing the 4-Cl and 3,4-Cl2 group at the phenyl ring
(compounds 17 and 18, respectively), whereas in A549 cells –
via the 3-Cl and 3,4-Cl2 substitution (compounds 16 and 18,
respectively). The derivative 15 with the Cl group at an ortho
position on the phenyl moiety, although displaying cytotoxic
effects in tumour cells, proved to be the lowest toxic for
normal cells in the series of chloro-substituted congeners,
particularly when investigated after 24 and 48 h of incubation.
Moving the Cl group to the meta position of the phenyl ringPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
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T47D and TOV112D cells), with an increased cytotoxicity
for A549 and HeLa cells after 24 and 48 h of incubation,
respectively, when compared to 15. Almost none of the
enhancement in the antiproliferative activity against tumour
cells was attained by introducing the chlorine atom into the
position para of the phenyl ring, as proved for 17 when
compared to 16. In the case of the antiproliferative active
compound with the 3-Cl substitution (16), introducing a
further Cl substituent at position para of the phenyl moiety
resulted in still antiproliferative active 3,4-Cl2 substituted
molecule (18), although revealing the decreased cytotoxicity
for normal cells after 24- and 48-h incubation periods.
The bioisosteric replacements of the CH3 group (susceptible
to oxidation in vivo (Patrick, 2009)) that is placed both in the
ortho and in the para position of the phenyl ring (compounds
11 and 12, respectively) with a Cl group (resistant to oxidative
biotransformation in vivo (Patrick, 2009)) led to in vitro
antiproliferative active bioisosteres (molecules 15 and 17,
respectively). The best balance of cytotoxicity versus more
selectivity was achieved by introducing a Cl group (compound
15) in the case of the ortho-substituted isosteres (11 and 15) or
a CH3 group (compound 12) in the case of para-substituted
isosteres (12 and 17).
Introducing the methoxy group at the ortho position of the
phenyl ring turned out to be the successful structural modifica-
tion leading to a decrease in the cytotoxicity towards normal
cells, which was particularly seen after 24 and 48 h of
incubation as confirmed in the case of the compound 14, when
compared to the parent structure (10).
Placing a methyl group ortho to the phenyl ring led to a
decrease in cytotoxicity towards normal cells only after
48- and 72-h incubation periods, as confirmed in the case of
the structure 11 (when compared to 10). Introducing a further
methyl group to the phenyl ring resulted in a decrease of toxic, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Table 2 The IC50 values for all novel fused azaisocytosine-like congeners.
Compound Incubation time IC50 values (mM)
a
Vero A549 HeLa T47D TOV112D
10 24 h >0.15 0.11 ± 0.011 0.09 ± 0.009 0.08 ± 0.010 0.09 ± 0.009
48 h 0.08 ± 0.009 0.08 ± 0.008 0.08 ± 0.009 0.08 ± 0.008 0.08 ± 0.010
72 h 0.08 ± 0.012 0.08 ± 0.010 0.08 ± 0.008 0.08 ± 0.008 0.08 ± 0.008
11 24 h 0.14 ± 0.018 0.10 ± 0.011 0.09 ± 0.009 0.12 ± 0.012 0.09 ± 0.007
48 h 0.10 ± 0.007 0.09 ± 0.009 0.08 ± 0.009 0.09 ± 0.009 0.08 ± 0.007
72 h 0.08 ± 0.008 0.07 ± 0.008 0.07 ± 0.009 0.08 ± 0.008 0.07 ± 0.007
12 24 h >0.14 >0.14 0.08 ± 0.008 0.08 ± 0.009 0.09 ± 0.007
48 h 0.09 ± 0.008 0.14 ± 0.016 0.08 ± 0.008 0.07 ± 0.007 0.08 ± 0.005
72 h 0.07 ± 0.011 0.09 ± 0.009 0.07 ± 0.007 0.07 ± 0.008 0.08 ± 0.006
13 24 h >0.14 >0.14 0.09 ± 0.008 0.09 ± 0.009 0.14 ± 0.010
48 h 0.14 ± 0.011 0.09 ± 0.010 0.08 ± 0.008 0.07 ± 0.006 0.08 ± 0.006
72 h 0.08 ± 0.011 0.08 ± 0.008 0.08 ± 0.008 0.07 ± 0.008 0.07 ± 0.008
14 24 h >0.14 >0.14 0.08 ± 0.007 0.09 ± 0.008 0.09 ± 0.008
48 h >0.14 0.09 ± 0.010 0.08 ± 0.009 0.08 ± 0.007 0.08 ± 0.008
72 h 0.09 ± 0.006 0.09 ± 0.010 0.07 ± 0.007 0.07 ± 0.007 0.07 ± 0.007
15 24 h >0.14 0.14 ± 0.013 0.10 ± 0.009 0.08 ± 0.006 0.08 ± 0.006
48 h 0.14 ± 0.016 0.08 ± 0.008 0.08 ± 0.008 0.07 ± 0.006 0.07 ± 0.007
72 h 0.08 ± 0.008 0.07 ± 0.008 0.07 ± 0.008 0.07 ± 0.006 0.07 ± 0.008
16 24 h 0.09 ± 0.008 0.08 ± 0.008 0.08 ± 0.007 0.07 ± 0.004 0.08 ± 0.007
48 h 0.08 ± 0.007 0.07 ± 0.008 0.07 ± 0.007 0.07 ± 0.006 0.07 ± 0.006
72 h 0.07 ± 0.006 0.07 ± 0.007 0.07 ± 0.008 0.07 ± 0.007 0.07 ± 0.007
17 24 h 0.14 ± 0.013 0.09 ± 0.008 0.08 ± 0.008 0.07 ± 0.006 0.08 ± 0.006
48 h 0.07 ± 0.007 0.07 ± 0.007 0.08 ± 0.008 0.07 ± 0.008 0.07 ± 0.006
72 h 0.07 ± 0.008 0.07 ± 0.007 0.07 ± 0.007 0.07 ± 0.007 0.07 ± 0.006
18 24 h >0.12 0.08 ± 0.008 0.07 ± 0.006 0.07 ± 0.005 0.07 ± 0.006
48 h 0.09 ± 0.010 0.06 ± 0.007 0.06 ± 0.005 0.06 ± 0.005 0.06 ± 0.006
72 h 0.06 ± 0.008 0.06 ± 0.007 0.06 ± 0.006 0.06 ± 0.008 0.06 ± 0.005
a Each value is the mean ± standard deviation.
10 M. Sztanke et al.effects of the derivative 13 for normal cells mostly after 24 and
48 h of incubation, when compared to 11. Placing a methyl
group para to the phenyl ring led to a decrease in cytotoxicity
against normal cells after 24- and 48-h incubation periods, as
confirmed in the case of the molecule 12 (when compared to
10).
Experimental results proved that the attachment of mostly
electron-donating moieties such as 4-CH3, 2,3-(CH3)2, 2-CH3O
and electron-withdrawing 2-Cl and 3,4-Cl2 groups at the phe-
nyl ring, enhanced the selectivity for malignant over normal
cells of the compounds 12, 13, 14, 15 and 18 after 24 h of their
incubation. However, they showed rather little selectivity after
48- and 72-h incubation periods.
3.3. Assessment of the drug-likeness of the investigated fused
azaisocytosine-containing congeners (10–18)
According to the Lipinski’s rule of five (Lipinski et al., 2001),
all the reported in this study unknown congeners (10–18) have
the increased chances of good oral bioavailability by the rea-
son of fact that they have the following: the calculated log P
values less than 5 and the overall molecular weights below
500 Da, not more than 5 H-bond donor and 10 H-bond accep-
tor sites. Furthermore, the analyzed compounds predicted toPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal obe conformationally stable as their molecules have less than
10 rotatable bonds, whereas their topological polar surface
areas are less than 140 A˚2. These predictable molecular
descriptors, shown in Table S1 in Supplementary material,
were in the optimum range as that reported for the orally
and intestinally bioavailable pharmaceutics (Veber et al.,
2002; Eartl et al., 2000; Palm et al., 1997).
3.4. Chromatographic behaviour and the individual retention
factors of novel solutes (10–18)
The chromatographic behaviour of this novel class of the com-
pounds (10–18) was established. The isocratic retention fac-
tors, logs k (Yamagami et al., 1990, 1994; Klein et al., 1988),
were measured directly by reversed phase liquid chromatogra-
phy (RPLC) on three different columns in 20 C (293 K) as
well as 37 C (310 K). Chromatographic analyses were carried
out using buffered aqueous eluent systems containing as an
organic modifier 40% (v/v) (log k 0.4 MeCN) and 50% (v/v) ace-
tonitrile (log k 0.5 MeCN). An immobilized artificial membrane
(IAM), an immobilized cholesterol (that imitate biological sys-
tems) and an internal surface reversal phase (ISRP), respec-
tively, were employed as three different stationary materials.
The choice of the endcapped stationary phases was aimed at, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Synthesis, structure elucidation, and determination of antiproliferative activities 11minimizing secondary retention mechanisms. It is well known
that HPLC columns without endcapping have significant
amounts of silanol groups capable of secondary silanophilic
interactions which interfere with the partitioning mechanism.
This is especially noticeable when employing acetonitrile as
the mobile phase component.
The primary advantages of the performed direct RPLC
measurements should be underlined. The retention parameters,
logs k, were employed as the descriptors of lipophilicity. Thus
this allowed not only to significantly shorten the retention
times of compounds under study but also significantly reduce
the overall time and costs of RPLC measurements that were
carried out. It should be noted that the reliable and repro-
ducible logs k of the compounds of interest are different fla-
vours of their lipophilicity. All these isocratic retention
factors that are the first time presented will be indispensable
in further bioactivity predictions.
The correlation matrix concerning the results obtained on
three different columns is listed in Table S2 in Supplementary
material. The plot correlating log k 0.4 MeCN, 310K and
log k 0.4 MeCN, 293K values measured on three different station-
ary phases is presented in Fig. S1A in Supplementary material.
On the other hand, the plot of logs k 0.5 MeCN, 310K versus logs
k 0.5 MeCN, 293K is shown in Fig. S1B in Supplementary
material. The obtained results showed the column with an
immobilized cholesterol is the most selective in relation to
the analyzed compounds because their experimental logs k
are the most varied. Furthermore, it has been shown that a
bit weaker selectivity to the analyzed solutes reveals the IAM
column, whereas the ISRP column seems to be the distinctly
less selective for these types of analytes as their determined
log k factors are the least varied.
It has been shown that the structure-dependent lipophilic
properties of the individual compounds have a remarkable
influence on their chromatographic behaviour and retention
factors (Table 3). This is, as expected, taking into account
the background theory of retention explaining that in the
RPLC measurements the retention is governed by hydropho-
bic forces and therefore the lipophilicity of the individual
solute is governing the retention (Cimpan et al., 2000; Dill
and Dorsey, 1994; Dorsey et al., 1989; Dorsey and Khaledi,
1993; Valko, 2004; Gocan and Cimpan, 2006; Kaliszan,
2007). It is obvious that the structure-retention behaviour of
solutes in reversed phase chromatographic investigations (that
are of dynamic nature) determinates their fundamental pro-
cesses of pharmacokinetic phase, e.g., liberation, absorption,
distribution, metabolism and elimination (LADME) that
occur in a living organism (Dorsey and Khaledi, 1993;
Kaliszan, 2007; Perisic-Janjic et al., 2011; Janicka et al., 2013).
The combined electronic effects of the groups within the
molecules investigated and resulting steric interactions may
have influence on their determined log k parameters (Table 3).
It seems that these ones although in part were capable of sig-
nificantly perturbing the reported earlier hydrophobicity con-
stant increment of some substituents attached to the
aromatic systems (Hansch and Leo, 1979; Fujita et al., 1964).
Effects of a number of electron-donating and electron-
withdrawing substituents attached at the phenyl moiety on
decreasing and increasing logs k were thoroughly investigated.
The parent compound (10) has a non-substituted electron-richPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal ophenyl as the first aromatic moiety attached at the N-8 of the
common template and the electron-withdrawing para-NO2
group at the second phenyl ring. All the solutes 11–14 possess
electron-donating substituents located at the first phenyl ring
in different positions and additionally the electron-
withdrawing NO2 group in the para position at the second
phenyl moiety. In turn, all the compounds 15–18 have
electron-withdrawing substituents located at the first phenyl
ring in different positions as well as the electron-withdrawing
NO2 group in the para position at the second phenyl moiety.
It has been confirmed that electron-donating substituents
located on the phenyl moiety decreased the logs k of the inves-
tigated compounds in the order: 2-CH3 > 2-CH3O> 4-CH3 >
2,3-(CH3)2, when the RPLC measurements were carried out on
the cholesterol column at both temperatures and both acetoni-
trile volume concentrations as well as on the IAM column at
20 C using 50% acetonitrile in the mobile phase. In turn,
the log k parameters of the same compounds decreased in
the order of 2-CH3 > 2-CH3O > 2,3-(CH3)2 > 4-CH3, when
the chromatographic measurements were performed on the
IAM column at 37 C employing 40% acetonitrile in the
mobile phase, on the IAM column at both temperatures
employing 50% acetonitrile and on the ISRP column at both
temperatures and both acetonitrile volume concentrations.
Furthermore, it has been observed that electron-withdrawing
substituents attached at the phenyl moiety decreased the log
k factors of the studied solutes in the order: 3,4-Cl2 > 4-Cl >
2-Cl > 3-Cl, when the chromatographic measurements were
carried out at both temperatures on the column with an immo-
bilized cholesterol as the stationary phase employing both ace-
tonitrile volume concentrations, on the IAM column using
50% acetonitrile in the mobile phase and on the ISRP column
employing 40% acetonitrile. In turn, the logs k of the same
compounds decreased in the order of 3,4-Cl2 > 4-Cl > 3-Cl >
2-Cl, when the chromatographic measurements were per-
formed at both temperatures on the IAM column employing
40% acetonitrile in the mobile phase and on the ISRP column
using 50% acetonitrile.
Introducing two electron-donating methyl groups to the
parent molecule (10) resulted in a noticeable decrease of the
determined logs k of the 2,3-(CH3)2-substituted compound
(18). The most probable explanation would account for the
steric hindrance of the modified molecule, which decreased
its lipophilicity. Generally, it has been confirmed that the log
k factors of the positional isomer with the para-Cl substitution
(17) are higher than those of the ortho-Cl and meta-Cl substi-
tuted isomers (15 and 16, respectively). Introducing the second
chlorine atom to the para-Cl and meta-Cl derivatives (16 and
17, respectively) evoked an increase in the log k parameters
of the 3,4-Cl2-substituted solute (18). Additionally, the deter-
mined retention factors of the ortho-substituted compounds
proved to be distinctly lower than those predicted by an
ACD/Percepta software. The decreasing and increasing exper-
imental log k values of the molecules with an ortho substitution
at the phenyl ring can be explained by taking into account the
ortho effect. The most probable hypothesis is that 2,3-(CH3)2
and 2-Cl substituents in the ortho position caused the steric
hindrance forcing-out-of-plane free rotation, whereas 2-CH3
and 2-CH3O groups were engaged in internal H-bond interac-
tions (Hsieh and Dorsey, 1993; Van de Waterbeemd et al.,, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Table 3 The in silico molecular descriptors that are related to pharmacokinetics, retention factors (logs k) measured directly for a
given system and calculated partition coefficients (expressed as logs P) of the compounds investigated.
Compound 10 11 12 13 14 15 16 17 18
log BB distribution 0.059 0.133 0.133 0.32 0.086 0.049 0.102 0.038 0.183
f u plasma 0.02 0.02 0.02 0.019 0.021 0.011 0.011 0.014 0.007
log BB permeation 1.11 0.96 0.96 0.77 0.93 1.01 1.12 1.15 1.13
log K HSA 5.1 5.16 5.16 5.18 5.17 5.42 5.4 5.38 5.75
% F 77 62 62 53 71 27 26 18 5
Pe, jejunum  104 [cm s1] 7.96 7.84 7.84 7.71 7.73 7.87 7.87 7.85 7.75
Caco-2  106 [cm s1] 223 232 232 238 218 236 236 230 241
log P 2.311 2.928 2.928 3.54 2.303 2.81 2.995 2.786 3.478
log k IAM, 0.4 MeCN, 293 K 0.091 0.402 0.139 0.086 0.18 0.033 0.043 0.364 0.661
log k IAM, 0.5 MeCN, 293 K 0.319 0.114 0.541 0.55 0.284 0.469 0.463 0.118 0.097
log k IAM, 0.4 MeCN, 310 K 0.138 0.448 0.075 0.041 0.241 0.024 0.047 0.412 0.709
log k IAM, 0.5 MeCN, 310 K 0.252 0.059 0.419 0.369 0.198 0.366 0.343 0.094 0.119
log k Cholester, 0.4 MeCN, 293 K 1.055 1.441 0.804 0.746 1.283 0.991 0.872 1.456 1.792
log k Cholester, 0.5 MeCN, 293 K 0.651 0.949 0.437 0.391 0.829 0.58 0.491 0.968 1.225
log k Cholester, 0.4 MeCN, 310 K 1.009 1.374 0.766 0.738 1.214 0.952 0.831 1.372 1.704
log k Cholester, 0.5 MeCN, 310 K 0.591 0.888 0.392 0.369 0.769 0.534 0.443 0.897 1.154
log k ISRP, 0.4 MeCN, 293 K 0.003 0.111 0.058 0.028 0.036 0.014 0.012 0.099 0.179
log k ISRP, 0.5 MeCN, 293 K 0.1 0.046 0.143 0.134 0.087 0.118 0.117 0.047 0.002
log k ISRP, 0.4 MeCN, 310 K 0.084 0.016 0.144 0.12 0.072 0.111 0.114 0.02 0.148
log k ISRP, 0.5 MeCN, 310 K 0.316 0.265 0.351 0.33 0.321 0.337 0.324 0.277 0.229
log BB distribution – distribution of the solute between the blood–brain; fu, plasma – fraction unbound of the solute in the plasma;
log BB permeation – permeation of the solute through the blood–brain barrier; log KHSA – binding of the compound with human albumin serum
and controlling the fraction unbound in body compartments in equilibrium with the plasma;%F – oral bioavailability of the solute after per os
administration at a dose of 50 mg; Pe, jejunum – human jejunal score (pH 6.5); Caco-2 permeability value – is employed for assessing the intestinal
absorption; log P – the calculated logarithms of n-octanol-water coefficients; log k IAM, 0.4 MeCN, 293K – the retention factors, log k obtained on
the immobilized artificial membrane (IAM)-type column with buffer-acetonitrile 0.4 v/v mobile phases at 20 C (293 K); log k IAM, 0.5 MeCN, 293K
– the retention factors, log k obtained on the IAM-type column with buffer-acetonitrile 0.5 v/v mobile phases at 20 C (293 K);
log k IAM, 0.4 MeCN, 310K – the retention factors, log k obtained on the IAM-type column with buffer-acetonitrile 0.4 v/v mobile phases at 37 C
(293 K); log k IAM, 0.5 MeCN, 310K – the retention factors, log k obtained on the IAM-type column with buffer-acetonitrile 0.5 v/v mobile phases
at 37 C (293 K); log k Cholester, 0.4 MeCN, 293K – the retention factors, log k obtained on the column with an immobilized cholesterol, as the
stationary phase with buffer-acetonitrile 0.4 v/v mobile phases at 20 C (293 K); log k Cholester, 0.5 MeCN, 293K – the retention factors, log k
obtained on the column with an immobilized cholesterol, as the stationary phase with buffer-acetonitrile 0.5 v/v mobile phases at 20 C (293 K);
log k Cholester, 0.4 MeCN, 310K – the retention factors, log k obtained on the column with an immobilized cholesterol, as the stationary phase with
buffer-acetonitrile 0.4 v/v mobile phases at 37 C (310 K); log k Cholester, 0.5 MeCN, 310K – the retention factors, log k obtained on the column with
an immobilized cholesterol, as the stationary phase with buffer-acetonitrile 0.5 v/v mobile phases at 37 C (310 K); log k ISRP, 0.4 MeCN, 293K
– the retention factors, log k obtained on the ISRP-type column with buffer-acetonitrile 0.4 v/v mobile phases at 20 C (293 K); log k ISRP, 0.5
MeCN, 293K – the retention factors, log k obtained on the ISRP-type column with buffer-acetonitrile 0.5 v/v mobile phases at 20 C (293 K);
log k ISRP, 0.4 MeCN, 310K – the retention factors, log k obtained on the ISRP-type column with buffer-acetonitrile 0.4 v/v mobile phases at 37 C
(310 K); log k ISRP, 0.5 MeCN, 310K – the retention factors, log k obtained on the ISRP-type column with buffer-acetonitrile 0.5 v/v mobile phases
at 37 C (310 K).
12 M. Sztanke et al.1996; Lambert, 1993; Carrupt et al., 1997). This could be the
cause why in our measurements 2,3-(CH3)2 and 2-Cl substi-
tuted molecules revealed decreased, whereas 2-CH3 and
2-CH3O ones had increased retention factors in relation to
the parent structure (10).
3.5. Chromatographic retention factors versus partitioning
lipophilicities
The relationships between computed log P values (by using an
ACD/Percepta software) and experimentally obtained log k
factors were carefully investigated.
Logs P versus logs k dependences were found to be explic-
itly linear for five compounds (10, 11, 14, 17 and 18) of nine
investigated (Fig. 2). The remaining four solutes (12, 13, 15
and 16), as typical outliers, had to be excluded from the regres-
sion equation. These outliers, although revealing the explicitly
overestimated log P values in in silico calculations, proved toPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal obe distinctly less lipophilic in the empirical RPLC measure-
ments. The same figure also shows that in the case of these
outliers there are significant objections against their calculated
lipophilicity indices. This means that the prediction of reliable
log P values of molecules 12, 13, 15 and 16 is impossible
and there is a clear need to verify the computed results
experimentally.
Statistics of the relationships obtained by plotting log P
versus log k values is presented in Table 4. The statistically
significant very strong linear correlations were disclosed
between the logarithms of predicted 1-octanol/water coeffi-
cients (expressed as log P values) and the logarithms of chro-
matographic retention parameters (expressed as the isocratic
log k factors) measured on IAM (R2 from 0.9684 to 0.9847;
p< 0.003) and ISRP (R2 from 0.9492 to 0.9923; p< 0.005)
columns. Logs P versus logs k correlations proved to be
also strong (R2 from 0.8895 to 0.9056) and statistically signif-
icant (p< 0.002) when chromatographic measurements were, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
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Figure 2 Log P versus log k relationships obtained for different HPLC systems at two temperatures (20 C (293 K) and 37 C (310 K)).
Table 4 Statistics of the relationships obtained by plotting logs P versus logs k (determined on three columns with different reversed-
phase materials).
Stationary phase uMeCN Temperature (K) a± SE b± SE S R
2 F p n Outliers
Equation: log P vs. log k: y = a (±SE) x + b (±SE)
IAM 0.4 293 2.186 ± 0.196 2.019 ± 0.077 0.087 0.9763 124 0.0016 5 12, 13, 15, 16
310 2.199 ± 0.229 1.905 ± 0.100 0.100 0.9684 92 0.0024 5 12, 13, 15, 16
0.5 293 2.926 ± 0.211 3.193 ± 0.044 0.070 0.9847 193 0.0008 5 12, 13, 15, 16
310 1.522 ± 0.052 3.087 ± 0.047 0.084 0.9781 134 0.0014 5 12, 13, 15, 16
Cholester 0.4 293 1.712 ± 0.342 0.356 ± 0.488 0.185 0.8929 26 0.0154 5 12, 13, 15, 16
310 1.834 ± 0.340 0.327 ± 0.460 0.173 0.9056 29 0.0127 5 12, 13, 15, 16
0.5 293 2.193 ± 0.446 0.734 ± 0.421 0.187 0.8896 25 0.0161 5 12, 13, 15, 16
310 2.240 ± 0.456 0.835 ± 0.401 0.188 0.8895 25 0.0161 5 12, 13, 15, 16
ISRP 0.4 293 6.757 ± 0.903 2.191 ± 0.095 0.127 0.9492 57 0.0049 5 12, 13, 15, 16
310 5.198 ± 0.428 2.732 ± 0.036 0.080 0.9801 148 0.0012 5 12, 13, 15, 16
0.5 293 12.029 ± 1.089 3.430 ± 0.072 0.087 0.9760 123 0.0016 5 12, 13, 15, 16
310 12.782 ± 0.651 6.361 ± 0.185 0.050 0.9923 386 0.0003 5 12, 13, 15, 16
Chromatographic parameters: uMeCN 0.4 and uMeCN 0.5 – indicate that mobile phases contained 0.4 (log k 0.4) and 0.5 (log k 0.5) volume fraction
of acetonitrile (MeCN), respectively; Statistical terms for the derived regression equations: SE – denotes the standard error of regression
coefficient, R2 – is the square correlation coefficient, S – denotes the standard error of estimate, F – denotes the value of the Fischer’s significance
test, p – is the statistical significance level, n – denotes a number of the solutes involved in the derived regression equation.
Synthesis, structure elucidation, and determination of antiproliferative activities 13performed on the column with an immobilized cholesterol as
the stationary phase. This means that novel lipophilicity
indices, giving a consistent scale of lipophilicity with thePlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal otrustworthy partitioning descriptors (expressed as log P val-
ues) of the compounds 10, 11, 14, 17 and 18, may be regarded
as their sustainable values of reference. However, the, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
14 M. Sztanke et al.computed log P values of solutes 12, 13, 15 and 16 cannot be
used as the trustworthy descriptors of their lipophilicity, as
confirmed above.
3.6. PCA
The principal component analysis-based approach was
employed to visualize the systematic trends in existed similar-
ities and dissimilarities between the chromatographic, parti-
tioning and pharmacokinetic parameters characterizing fused
azaisocytosine-like congeners of interest (10–18). The overall
twenty data set variables including: the chromatographic
retention factors (log k IAM 0.4, 293K, log k IAM 0.5, 293K,
log k IAM 0.4, 310K, log k IAM 0.5, 310K, log k Cholester 0.4, 293K,
log k Cholester 0.5, 293K, log k Cholester 0.4, 310K, log k Cholester 0.5, 310K,
log k ISRP 0.4, 293K, log k ISRP 0.5, 293K, log k ISRP 0.4, 310K,
log k ISRP 0.5, 310K), the predicted n-octanol/water
partitioning parameters (expressed as log P values) and the
in silico calculated molecular descriptors (log BBpermeation, log
BBdistribution, log KHSA,%F, fu, plasma, Caco-2, Pe, jejunum) that
are relevant to pharmacokinetics of the investigated com-
pounds were submitted to a rational PCA-based approach.
Three principal components explained 64.9%, 84.6% and
95.5% of the total variance, respectively. It should be noted
that the results obtained by the principal component (see the
loading plot presented in Fig. 3A) and cluster variables (see
the dendrogram shown in Fig. 3B) analyses are consistent,
confirming high trends in similarity between the analyzed
chromatographic, partitioning and bioactivity parameters.
The loading plot (Fig. 3A) presents the relationships
between all the variables after subjecting them to PCA. The
majority of data set variables, including valuable bioactivity
descriptors such as Caco-2, log KHSA, log BBdistribution, all
determined experimentally retention factors as well as the cal-
culated partitioning coefficient logarithms, logs P proved to be
similar to each other. In this case the in silico bioactivity
descriptors were proportional to the retention parameters both
determined experimentally and calculated in silico. All these
data set variables formed an ‘‘acute arrow” on the right side
of the chart. In turn, the other pharmacokinetic descriptor
variables such as Pe, jejunum, %F, fu, plasma, log BBpermeation
proved to be inversely proportional to the determined
logarithms of retention factors as well as to the predicted
logarithms of partition coefficients. All these data set variables
formed an ‘‘acute arrow” on the left side of the chart.
Furthermore, the score plot (Fig. 3C) reveals the trends in
similarities and dissimilarities between molecular structures
of the compounds that were tested according to the chromato-
graphic, partitioning and bioactivity variables. The investi-
gated compounds have been divided into two separate
clusters due to differences in their molecular structures. The
first explicitly linear cluster is associated with five more
lipophilic solutes (10, 11, 14, 17 and 18) and the second cluster
(with the scattered data points) is formed for four less lipophi-
lic analytes (12, 13, 15 and 16). Such grouping of the tested
solutes is most likely directly due to similarities in their reten-
tion mechanism (as evidenced by their logs k) obtained on
different RPLC materials. The diverse grouping on the ana-
lyzed compounds may also suggest that the retention of each
group of substances is controlled by the different net effect
of intermolecular forces between the solute on subsequentPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal oreversed phase materials and the mobile phase (Kaliszan,
2007; Perisic-Janjic et al., 2011). It cannot be excluded that
clustering of the compounds 12, 13, 15 and 16 may be
presumably evoked by more complicated steric and electronic
effects within their molecules that have a significant influence
on their retention behaviour and consequently on bioactivity
descriptors.
3.7. Correlations between chromatographic lipophilicity
parameters and in silico calculated pharmacokinetic descriptors
The data sets of the determined retention factors (log k) on
three different RPLC columns as well as in silico bioactivity
descriptors (e.g.,%F, fu, plasma, log KHSA, log BBdistribution,
log BBpermeation, Caco-2, Pe, jejunum) were correlated with the
goal of evaluating whether the lipophilicity parameters have
influence on the pharmacokinetic properties of our novel com-
pounds. This approach was performed with the purpose of
preselecting the lead candidates for further in vivo studies with
optimum lipophilicity ranges relevant to satisfactory pharma-
cokinetics. Knowledge about pharmacokinetic properties of
compounds with sufficient in vitro biological activities is
especially important before subjecting them to further in vivo
investigations. It is commonly known that poor pharmacoki-
netics, in the majority cases, results in drug candidate failure.
Therefore, in silico predictive models are very helpful at an
early discovery phase of new biologically active compounds
that are considered as potential drug candidates (Guerra
et al., 2010; Matysiak et al., 2015).
All the in silico calculated pharmacokinetic descriptors of
the investigated solutes are listed in Table 3. %F value is used
in an early phase of the lead candidate selection process for
predicting the bioavailability of the solute after per os admin-
istration, whereas the fu, plasma predictor is used for assessing a
fraction unbound of the compound of interest in the plasma
(e.g., actually active). Log KHSA value is employed for predict-
ing the solute binding with human serum albumin as the most
significant protein component. Caco-2 and Pe, jejunum predic-
tors are used for assessing the intestinal absorption and an
effective transport in human jejunum, respectively. Log BBdis-
tribution value predicts the distribution of the individual solute
between the blood–brain, whereas log BBpermeation value pre-
dicts the ability of the solute to penetrate the blood–brain
barrier.
Plots of the in silico pharmacokinetic descriptors against the
experimental retention factors are shown in Fig. 4A–C and
apart from that in Fig. S2 in Supplementary material. The
described correlations between physico-chemical properties
strictly related to pharmacokinetics and retention factors of
the analyzed new compounds on different reversed phase
stationary materials are presented in Table 5 and apart from
that in Table S3 in Supplementary material. The determined
log k factors proved to be applicable in predictions of some
fundamental pharmacokinetic properties of the studied solutes
such as%F, f u, plasma, log KHSA values.
Fig. 4A shows the relationships between the calculated oral
bioavailability values (expressed as %F) and the experimental
retention factors. These dependences are described by two
quadratic equations that were found to be separated for
solutes 15–18 and 10–14. The statistically significant and very
strong curvilinear relationships (R2 in the range from 0.9979 to, determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
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Figure 3 Loading plot (A), dendrogram (B) and score plot of PC2 against PC1 for the PCA-based approach (C).
Synthesis, structure elucidation, and determination of antiproliferative activities 15
Please cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation, determination of antiproliferative activities, lipophilicity indices and pharma-
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
A0,500,250,00
80
40
0
0,0-0,2-0,4 1,81,20,6 1,00,5
0,20,10,0 0,0-0,1 0,80,40,0 0,00-0,25
80
40
0
1,61,20,8
80
40
0
1,000,750,50 0,10,0-0,1 -0,25-0,30-0,35
log k (IAM, 0.4, 293K)
%
F
log k (IAM, 0.5, 293K) log k (Chol, 0.4, 293K) log k (Chol, 0.5, 293K)
log k (ISRP, 0.4, 293K) log k (ISRP, 0.5, 293K) log k (IAM, 0.4, 310K) log k (IAM, 0.5, 310K)
log k (Chol, 0.4, 310K) log k (Chol, 0.5, 310K) log k (ISRP, 0.4, 310K) log k (ISRP, 0.5, 310K)
solutes 10-14
solutes 15-18
B
0,500,250,00
0,020
0,015
0,010
0,0-0,2-0,4 1,51,0 1,20,80,4
0,20,10,0 0,0-0,1 0,50,0 0,0-0,2-0,4
0,020
0,015
0,010
1,61,20,8
0,020
0,015
0,010
1,000,750,50 0,10,0-0,1 -0,25-0,30-0,35
log k (IAM, 0.4, 293K)
fu
, p
la
sm
a
log k (IAM, 0.5, 293K) log k (Chol, 0.4, 293K) log k (Chol, 0.5, 293K)
log k (ISRP, 0.4, 293K) log k (ISRP, 0.5, 293K) log k (IAM, 0.4, 310K) log k (IAM, 0.5, 310K)
log k (Chol, 0.4, 310K) log k (Chol, 0.5, 310K) log k (ISRP, 0.4, 310K) log k (ISRP, 0.5, 310K)
solutes 10-14
solutes 15-18
C
0,500,250,00
5,6
5,4
5,2
0,0-0,2-0,4 1,81,20,6 1,00,5
0,20,10,0 0,0-0,1 0,80,40,0 0,00-0,25
5,6
5,4
5,2
1,61,20,8
5,6
5,4
5,2
1,000,750,50 0,10,0-0,1 -0,25-0,30-0,35
log k (IAM, 0.4, 293K)
lo
g 
K
, H
SA
log k (IAM, 0.5, 293K) log k (Chol, 0.4, 293K) log k (Chol, 0.5, 293K)
log k (ISRP, 0.4, 293K) log k (ISRP, 0.5, 293K) log k (IAM, 0.4, 310K) log k (IAM, 0.5, 310K)
log k (Chol, 0.4, 310K) log k (Chol, 0.5, 310K) log k (ISRP, 0.4, 310K) log k (ISRP, 0.5, 310K)
solutes 10-14
solutes 15-18
Figure 4 Relationships between pharmacokinetic descriptors and retention factors: (A) %F predictors versus log k factors; (B) f u plasma
predictors versus log k factors; (C) log K HSA predictors versus log k factors.
16 M. Sztanke et al.0.9999) were identified between the %F predictors and the log
k factors of compounds 15–18 established on IAM and ISRP
columns. %F versus logs k relationships were again very
strong (R2 in the range from 0.9965 to 0.9985) when the mea-
surements were performed on the column with an immobilized
cholesterol. The disclosed curvilinear shapes of these correla-
tion lines indicate that an enhancement in the solutes’
lipophilicities (expressed as logs k) reduces their bioavailability
after per os administration. In turn, %F values of the com-
pounds 10–14 plotted against the log k factors determined
on the cholesterol column at the temperature of 20 C revealed
also statistically significant and very strong parabolic correla-
tions (R2 = 0.9746 and 0.9797).
Fig. 4B presents the relationships between the pharmacoki-
netically active fraction unbound in the plasma (f u, plasma) and
the determined experimentally retention factors. The parabolic
shape of shown correlation lines suggests that there exists anPlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal ooptimum range of lipophilicity providing a proper binding of
the solute in the plasma. The relationships between the
f u, plasma predictors and the chromatographic retention param-
eters are described by quadratic equations for solutes 15–18.
The strongest and statistically significant correlations were
identified by plotting f u, plasma predictors versus the log k
factors obtained from measurements that were performed at
20 C on IAM (R2 = 0.9988 and 0.9992) and ISRP
(R2 = 0.9993 and 0.9996) columns. In turn, in the case of
solutes revealing lower binding with plasma proteins and form-
ing the separate group (10–14) no effect of the retention factors
on their optimal binding with plasma was observed. All the
tested substances (10–18) predicted to have a high protein
binding behaviour (according to the known protein binding
classification (Idaidek and Arafat, 2012; Amidon et al.,
1995)) as their overall fraction unbound in human blood
plasma is relatively low (<0.1)., determination of antiproliferative activities, lipophilicity indices and pharma-
f Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.04.002
Table 5 Statistics of the relationships obtained by plotting the in silico molecular descriptors related to pharmacokinetics versus log k factors.
Stationary phase uMeCN Temperature (K) a± SE b± SE c± SE S R
2 F p n Compounds
Equation:%F vs. log k: y = a (±SE) x2 + b (±SE) x + c (±SE)
IAM 0.4 293 185.079 ± 115.101 59.541 ± 34.709 68.142 ± 4.854 8.237 0.6032 1.6 0.3968 5 10–14
32.720 ± 7.617 10.357 ± 4.599 26.143 ± 0.492 0.764 0.9981 266 0.0434 4 15–18
310 210.667 ± 110.859 88.434 ± 43.081 64.438 ± 4.190 7.417 0.6783 2.2 0.3217 5 10–14
30.843 ± 5.581 8.968 ± 4.038 26.879 ± 0.447 0.529 0.9991 554 0.0300 4 15–18
0.5 293 317.289 ± 100.678 199.729 ± 71.595 42.947 ± 10.846 4.799 0.8653 6.5 0.1347 5 10–14
63.608 ± 11.237 61.658 ± 4.810 11.588 ± 0.528 0.698 0.9984 319 0.0396 4 15–18
310 380.403 ± 289.056 163.568 ± 143.267 54.365 ± 15.185 9.093 0.5164 1.1 0.4836 5 10–14
58.538 ± 8.947 59.214 ± 2.590 12.893 ± 0.351 0.424 0.9994 861 0.0241 4 15–18
Cholester 0.4 293 157.310 ± 19.866 353.779 ± 43.173 12.074 ± 22.204 2.085 0.9746 38.4 0.0254 5 10–14
28.302 ± 5.262 51.960 ± 13.992 2.658 ± 8.649 0.853 0.9977 213 0.0484 4 15–18
310 178.776 ± 38.556 385.549 ± 80.506 131.285 ± 39.935 3.494 0.9286 13.1 0.0714 5 10–14
39.502 ± 6.986 49.969 ± 17.710 5.377 ± 10.461 1.041 0.9965 143 0.0591 4 15–18
0.5 293 243.733 ± 27.723 338.998 ± 36.847 41.001 ± 11.129 1.865 0.9797 48.2 0.0203 5 10–14
47.471 ± 6.741 52.225 ± 11.527 12.168 ± 4.392 0.679 0.9985 336 0.0386 4 15–18
310 274.359 ± 54.935 354.987 ± 68.146 37.844 ± 19.147 3.254 0.9381 15.2 0.0619 5 10–14
48.180 ± 8.414 46.652 ± 13.416 15.215 ± 4.734 0.810 0.9979 236 0.0460 4 15–18
ISRP 0.4 293 1545.96 ± 1593.22 110.460 ± 123.190 69.210 ± 6.690 10.665 0.3349 0.6 0.6651 5 10–14
448.029 ± 89.381 37.608 ± 14.348 26.094 ± 0.432 0.671 0.9985 344 0.0381 4 15–18
310 1948.110 ± 1588.420 211.860 ± 209.330 66.440 ± 4.480 9.736 0.4457 0.9 0.5543 5 10–14
145.628 ± 55.517 77.354 ± 3.923 19.631 ± 0.791 0.802 0.9979 241 0.0456 4 15–18
0.5 293 5754.990 ± 3459.230 1026.090 ± 669.050 27.200 ± 29.450 8.036 0.6224 1.7 0.3776 5 10–14
1204.700 ± 236.148 319.00 ± 29.883 5.650 ± 0.645 0.682 0.9985 333 0.0387 4 15–18
310 5126.280 ± 6517.87 3104.350 ± 3979.380 399.850 ± 602.700 11.395 0.2407 0.4 0.7593 5 10–14
1129.230 ± 87.159 844.040 ± 49.423 129.090 ± 6.863 0.206 0.9999 366 0.0117 4 15–18
Equation: fu, plasma vs. log k: y = a (±SE) x
2 + b (±SE) x + c (±SE)
IAM 0.4 293 0.008 ± 0.011 0.003 ± 0.003 0.020 ± 0.001 0.001 0.3611 0.6 0.6389 5 10–14
0.047 ± 0.002 0.023 ± 0.001 0.01 ± 0.000 0.001 0.9988 417 0.0346 4 15–18
310 0.010 ± 0.011 0.005 ± 0.004 0.020 ± 0.000 0.001 0.4320 0.8 0.5680 5 10–14
0.049 ± 0.005 0.030 ± 0.003 0.010 ± 0.000 0.001 0.9936 78 0.0800 4 15–18
0.5 293 0.016 ± 0.014 0.009 ± 0.010 0.019 ± 0.002 0.001 0.5409 1.2 0.4591 5 10–14
0.077 ± 0.002 0.036 ± 0.001 0.011 ± 0.000 0.001 0.9992 633 0.0281 4 15–18
310 0.014 ± 0.027 0.005 ± 0.013 0.020 ± 0.001 0.001 0.2831 0.4 0.7169 5 10–14
0.097 ± 0.013 0.032 ± 0.004 0.012 ± 0.001 0.001 0.9876 40 0.1114 4 15–18
Cholester 0.4 293 0.007 ± 0.006 0.016 ± 0.012 0.011 ± 0.006 0.001 0.6482 1.9 0.3518 5 10–14
0.028 ± 0.011 0.070 ± 0.028 0.030 ± 0.017 0.002 0.8979 5 0.3195 4 15–18
310 0.008 ± 0.007 0.07 ± 0.015 0.011 ± 0.007 0.001 0.6008 1.6 0.3992 5 10–14
0.030 ± 0.012 0.071 ± 0.030 0.029 ± 0.018 0.002 0.38929 5 0.3273 4 15–18
0.5 293 0.010 ± 0.009 0.015 ± 0.012 0.015 ± 0.004 0.001 0.6299 1.8 0.3701 5 10–14
0.045 ± 0.017 0.0725 ± 0.028 0.015 ± 0.011 0.001 0.9018 5 0.3133 4 15–18
310 0.011 ± 0.011 0.015 ± 0.013 0.015 ± 0.004 0.001 0.5931 1.5 0.4069 5 10–14
(continued on next page)
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Table 5 (continued)
Stationary phase uMeCN Temperature (K) a± SE b± SE c± SE S R
2 F p n Compounds
0.046 ± 0.018 0.070 ± 0.028 0.012 ± 0.010 0.002 0.9880 5 0.3193 4 15–18
ISRP 0.4 293 0.071 ± 0.131 0.008 ± 0.010 0.020 ± 0.001 0.001 0.2338 0.4 0.7662 5 10–14
0.627 ± 0.018 0.081 ± 0.003 0.012 ± 0.000 0.001 0.9993 762 0.0256 4 15–18
310 0.090 ± 0.143 0.008 ± 0.019 0.020 ± 0.001 0.001 0.2275 0.3 0.7725 5 10–14
0.311 ± 0.009 0.006 ± 0.001 0.014 ± 0.000 0.001 0.9994 780 0.0253 4 15–18
0.5 293 0.259 ± 0.343 0.042 ± 0.066 0.019 ± 0.003 0.001 0.3626 0.6 0.6374 5 10–14
1.636 ± 0.039 0.227 ± 0.005 0.007 ± 0.000 0.001 0.9996 1151 0.0208 4 15–18
310 0.121 ± 0.563 0.072 ± 0.344 0.110 ± 0.052 0.001 0.0324 0.1 0.9676 5 10–14
1.839 ± 0.594 1.074 ± 0.337 0.143 ± 0.047 0.001 0.9312 7 0.2623 4 15–18
Equation: log KHSA vs. log k: y = a (±SE) x
2 + b (±SE) x + c (±SE)
IAM 0.4 293 0.396 ± 0.548 0.114 ± 0.165 5.146 ± 0.023 0.039 0.2149 0.3 0.7851 5 10–14
1.880 ± 0.200 0.685 ± 0.121 5.381 ± 0.013 0.020 0.9957 116 0.0657 4 15–18
310 0.467 ± 0.574 0.176 ± 0.223 5.153 ± 0.022 0.038 0.2465 0.4 0.7535 5 10–14
1.968 ± 0.009 0.960 ± 0.006 5.441 ± 0.001 0.010 1.000 710 0.0027 4 15–18
0.5 293 0.711 ± 0.749 0.456 ± 0.533 5.207 ± 0.081 0.036 0.3501 0.6 0.6499 5 10–14
3.215 ± 0.146 1.790 ± 0.062 5.546 ± 0.007 0.009 0.9991 568 0.2967 4 15–18
310 0.844 ± 1.264 0.383 ± 0.627 5.183 ± 0.066 0.040 0.1927 0.3 0.8073 5 10–14
3.894 ± 0.089 1.636 ± 0.026 5.500 ± 0.003 0.004 0.9998 2626 0.0138 4 15–18
Cholester 0.4 293 0.435 ± 0.286 0.952 ± 0.622 5.643 ± 0.320 0.030 0.5400 1.2 0.4600 5 10–14
1.141 ± 0.431 2.709 ± 1.147 6.931 ± 0.709 0.070 0.9474 9 0.2295 4 15–18
310 0.478 ± 0.350 1.006 ± 0.731 5.653 ± 0.362 0.032 0.4872 1.0 0.5128 5 10–14
1.213 ± 0.466 2.725 ± 1.182 6.862 ± 0.698 0.070 0.9479 10 0.2282 4 15–18
0.5 293 0.694 ± 0.432 0.932 ± 0.575 5.434 ± 0.174 0.029 0.5684 1.4 0.4316 5 10–14
1.045 ± 0.235 3.051 ± 0.777 6.130 ± 0.225 0.044 0.9789 24 0.1453 4 15–18
310 0.763 ± 0.514 0.952 ± 0.637 5.419 ± 0.179 0.030 0.5274 1.2 0.4726 5 10–14
1.929 ± 0.729 2.654 ± 1.163 6.234 ± 0.410 0.040 0.9468 9 0.2306 4 15–18
ISRP 0.4 293 2.583 ± 6.351 0.131 ± 0.491 5.146 ± 0.027 0.043 0.0779 0.1 0.9331 5 10–14
25.526 ± 1.295 2.466 ± 0.208 5.374 ± 0.006 0.010 0.9990 490 0.0319 4 15–18
310 3.749 ± 6.702 0.423 ± 0.883 5.153 ± 0.033 0.041 0.1390 0.2 0.8610 5 10–14
11.920 ± 1.244 0.882 ± 0.088 5.358 ± 0.018 0.018 0.9965 143 0.0590 4 15–18
0.5 293 12.335 ± 16.758 2.259 ± 3.244 5.241 ± 0.143 0.039 0.2255 0.3 0.7745 5 10–14
66.847 ± 3.639 10.566 ± 0.461 5.729 ± 0.010 0.011 0.9998 420 0.0345 4 15–18
310 11.824 ± 23.801 7.126 ± 14.531 6.215 ± 2.201 0.042 0.1166 0.2 0.8834 5 10–14
76.139 ± 11.794 45.989 ± 6.688 12.286 ± 0.929 0.028 0.9916 60 0.0916 4 15–18
All statistical terms for the derived regression equations are explained underneath Table 5.
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Synthesis, structure elucidation, and determination of antiproliferative activities 19Fig. 4C also shows plots correlating affinities for human
serum albumin (log KHSA) of the compounds 15–18 and their
retention factors determined experimentally. These relation-
ships are described by quadratic equations. In this case it is
seen that only a significant increase in the logs k of the solutes
of interest evokes a significant enhancement in their binding
with albumin in the human serum. The strongest and
statistically significant correlations were derived by plotting
log KHSA predictors versus the log k values determined on
IAM column at 37 C (R2 = 0.9998 and 1.0000) and on ISRP
column at 20 C (R2 = 0.9990 and 0.9998). Our results are
consistent with some findings presented in earlier studies
(Kaliszan et al., 1996; Ong et al., 1996; Caldwell et al., 1998;
Nasal et al., 1994; Barbato et al., 2007; Stewart and Chan,
1998; Chan et al., 2005; Janicka and Pachuta-Stec, 2014) that
described the advantages in bioactivity predictions of the
retention parameters determined on IAM-type columns that
imitate biosystems. In contrast, in the case of compounds
10–14 no effect of their lipophilicity on an optimal binding
with human serum albumin was observed.
All the investigated small molecules (10–18) predicted to be
highly permeable and therefore they are expected to be easily
transported through the intestinal epithelium (according to
the adopted classification of Caco-2 cell permeability
(Yamashita et al., 2000; Yazdanian et al., 1998)). The com-
puted Caco-2 values ranged from 218  106 cm s1 for solute
14 to 241  106 cm s1 for the most lipophilic compound 18.
In turn, the calculated Pe, jejunum values ranged from
7.71  104 cm s1 for analyte 13 to 7.96  104 cm s1 for
the parent compound 10. These values indicate that all these
solutes should be fast absorbed in the human jejunum at phys-
iological pH (Stezpnik et al., 2014). Nevertheless, in the case of
all the compounds that were studied no influence of the logs k
on Caco-2 as well as Pe, jejunum predictors, respectively, was
observed (Fig. S2 and Table S3 in Supplementary material).
Amongst this novel class of fused azaisocytosine-like con-
geners only molecules revealing the optimum lipophilicity
range relevant to satisfactory pharmacokinetics may be
regarded as the most promising candidates of the series for fur-
ther in vivo testing. These lead structures emerged from a
rational approach aiming at processing the experimental reten-
tion factors in bioactivity predictions. Statistically significant
and highly predictive relationships presented in this study con-
firmed that the liquid chromatography with suitable reversed
phase materials of diverse separation properties (including
those imitating biosystems) is an excellent in vitro system that
may be successfully used for assessing some fundamental phar-
macokinetic properties (such as %F, f u, plasma, log KHSA) of
our new solutes from their retention factors measured directly
for given systems, as described above in detail. Pharmacoki-
netic properties of our novel compounds will be of value
during their further in vivo investigations and finally all these
descriptors of bioavailability could be validated in an animal
model.
4. Conclusion
A novel class of fused azaisocytosine-containing congeners (10–18), as
the anticipated false building blocks of nucleotides required for DNA
synthesis, has been obtained employing the straightforward synthetic
strategy. Their efficient and scalable synthesis was performed under
mild reaction conditions with relatively good overall yields. All thePlease cite this article in press as: Sztanke, M. et al., Synthesis, structure elucidation
cokinetic properties of novel fused azaisocytosine-like congeners. Arabian Journal ooriginal compounds demonstrated superior antiproliferative effects in
three tumour cell lines to those of the commonly used folate
antimetabolite – pemetrexed. The most promising candidates for
designing more selective cytotoxic agents seem to be the representatives
12, 13, 14, 15 and 18 as they reveal a lower toxicity for normal cells of
the same epithelial origin after 24-h incubation period. The lipophilic-
ity factors were determined by RPLC on three diverse stationary
materials for all novel molecules and were used in correlation studies
with in silico pharmacokinetic properties. A number of compounds
also showed the optimum values of logs k significantly correlated with
in silico bioactivity descriptors (such as %F – in the case of 10–18
and f u, plasma, log KHSA – in the case of 15–18) required for the satis-
factory pharmacokinetics in vivo. Therefore, these molecules seem to
be the most promising lead structures that may be subjected to further
more detailed drug development investigations.
Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.arabjc.
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